

State of Oklahoma SoonerCare

Mvasi[®] (Bevacizumab-awwb) Prior Authorization Form

Member Name:	Date of Birth:	Member ID#:
Drug Information		
□Physician billing (HCPCS cod	le:) □Pharma	cy billing (NDC:)
Dose: Regin	men: S	tart Date (or date of next dose):
Billing Provider Information		
Provider NPI:	Provider Name:	
Provider Phone:	Provider Fax:	
Prescriber Information		
Prescriber NPI:	Prescriber Name:	
Prescriber Phone:	Prescriber Fax:	Specialty:
	Criteria	
Zirabev [®] (bevacizumab-bv	y significant reason why the me	mber cannot use Avastin [®] (bevacizumab) or
3. Has the member experienced a lf yes, please specify adverse read	e of progressive disease while any adverse drug reactions relactions:	on Mvasi [®] therapy? Yes No Ited to Mvasi [®] therapy? Yes No
Prescriber Signature: I certify that the indicated treatment knowledge. Failure to complete this form	t is medically necessary and all	_ Date:information is true and correct to the best of my

PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:

University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit

> Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.

Pharm – 166 07/20/2022